Cell-intrinsic effects such as induction of apoptosis and/or inhibition of cell proliferation have been proposed as the major anti-tumor responses to histone deacetylase inhibitors (HDACi). These compounds can also mediate immunemodulatory effects that may also contribute to their anti-cancer effects. However, HDACi can also induce anti-inflammatory, and potentially immunosuppressive, outcomes. We therefore sought to clarify the role of the immune system in mediating the efficacy of HDACi in a physiological setting, utilising pre-clinical, syngeneic murine models of haematological malignancies and solid tumors. We showed an 
Introduction
Histone deacetylase inhibitors (HDACi) are FDA-approved agents used for the treatment of haematological malignancies (1, 2) . HDACi can induce a range of tumor cell-intrinsic biological responses such as induction of apoptosis, senescence, differentiation or inhibition of cell cycle progression, that could account for their antitumor activities. Indeed, using pre-clinical models, we, and others, have previously demonstrated that induction of tumor cell apoptosis is obligate for HDACi to reduce tumor burden in vivo and enhance the survival of tumor-bearing mice (3, 4) . In addition to direct effects on tumor cell growth and survival, the therapeutic effects of HDACi may also involve effects on the host immune and vascular systems (5) . For example, treatment of tumor cells with HDACi can enhance expression of putative tumor antigens (6) , MHC class I and II molecules and associated machinery (7, 8) , costimulatory molecules (9) and NK cell-activating ligands (10, 11) , and enhance phagocytosis by DCs (12) . This could augment the immunogenicity and antigen presenting capacity of tumor cells and increase their susceptibility to killing by cytotoxic lymphocytes (CTLs). Indeed, HDACi have been shown to greatly enhance the sensitivity of tumors to immunotherapy. This combinatorial approach has proven highly successful against a range of malignancies in vivo suggesting HDACi may also engage and mediate an anti-tumor immune response during cancer therapy (12) (13) (14) . Author Manuscript Published OnlineFirst on October 24, 2013; DOI: 10.1158/0008-5472.CAN- lymphocytes, was abrogated by HDACi. HDACi are also thought to have antiinflammatory properties and can reduce the bacterial lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines by human peripheral blood mononuclear cells (PBMCs) and in mice (17) . In addition to their direct antiinflammatory actions, HDACi can moderate immune function via induction of
Foxp3
+ T regs (14, 18) and suppression of CD4 + T cell responses to TCR activation (19) . Furthermore, pre-clinical and clinical trials have been initiated utilising HDACi to treat autoimmune and inflammatory conditions such as systemic lupus erythematosus [SLE; (20, 21) ] and colitis (18) . 
Materials and Methods

In vivo tumor models
Quantitative PCR for IFN-γ expression
Naïve B cells were isolated from the spleen of WT mice using CD45R (B220)
MicroBeads ( 
IFN-γ detection
Serum was extracted from mouse blood samples and interrogated for IFN-γ using the BD Cytometric Cytokine Bead Array mouse IFN-γ Flex Set and Cell Signaling
Master Buffer Set (BD Biosciences) as per the manufacturer's instructions. Statistical significance was assessed using Prism software (GraphPad Software) and calculated by the Mann-Whitney Test (non-parametric data), or a log-rank sum test (for overall survival), p-value > 0.05 was always considered statistically significant.
Statistical analysis
Results
An intact immune system is required for the robust anti-cancer activities of vorinostat against a colon carcinoma
We previously demonstrated that vorinostat treatment of MC38 colon adenocarcinoma cells significantly enhanced phagocytosis by DCs (12) . To further determine whether vorinostat enhanced the immunogenicity of MC38 tumor cells, we assessed markers of immunogenic cell death (22) following exposure to vorinostat. (Fig. 1A) . Strikingly, the anti-tumor effect of vorinostat was lost in Rag-2γc -/-mice (Fig. 1A) . This was not due confirming appropriate penetration of HDACi into the tumor mass in both immunecompromised and -competent mice (Fig. 1B) . Similarly, TUNEL staining revealed tumor cell apoptosis in tumors from both vorinostat-treated WT and Rag-2γc -/-mice (Fig. 1C, D) . These data suggest an intact immune system is required to mediate the long-term, complete anti-cancer effects of vorinostat against solid malignancies.
An intact immune system is required for the sustained anti-cancer effects of vorinostat against an aggressive lymphoma
Our laboratory has previously demonstrated that HDACi are highly efficacious against primary B cell lymphomas arising from Eμ-myc transgenic mice (3, 4, 25) .
Therefore we utilised the Eμ-myc model to confirm the observation that HDACi required an intact immune system for sustained therapeutic efficacy. As expected, the treatment of WT mice bearing established Eμ-myc tumors with vorinostat significantly enhanced survival compared to control treatment ( Fig. 2A and Supplementary Table S1 ). Although vorinostat also significantly enhanced the survival of Rag-2γc -/-mice transplanted with the same Eμ-myc tumor used in WT mice, vorinostat-treated, tumor-bearing Rag-2γc -/-mice succumbed to lymphoma significantly earlier than vorinostat-treated, tumor-bearing WT mice ( Fig. 2A and Supplementary Table S1 ). Consistent with results using the MC38 solid tumor line S2B ). Together these data suggest Rag-2γc -/-mice succumbed to lymphoma despite vorinostat treatment due to lack of a functional immune system.
Anti-cancer activities of HDACi, but not etoposide, are mediated by the immune system
We extended our discovery that sustained anti-cancer effects of vorinostat required an intact host immune system by utilising a second, genetically distinct Eμ-myc lymphoma and a second HDACi, panobinostat. Consistent with Figure 2A , vorinostat did prolong the survival of Rag-2γc -/-mice bearing a genetically different Eμ-myc lymphoma compared to the control-treated group (Fig. 3A and Supplementary Table   S1 ). However, tumor-bearing Rag-2γc -/-mice again succumbed to disease significantly earlier than tumor-bearing WT mice despite vorinostat treatment ( Fig.   3A and Supplementary Table S1 ). Also, in agreement with our previous publication (4), WT mice bearing established Eμ-myc lymphoma responded successfully to panobinostat and survival was significantly enhanced compared to control treatment (Fig. 3B and Supplementary Table S1 ). Similarly, Rag-2γc -/-mice bearing established
Eμ-myc lymphoma treated with panobinostat survived significantly longer than control treated Rag-2γc -/-mice, however Rag-2γc -/-mice also succumbed to Table S1 ). Together these data suggest that an intact immune system is required for prolonged therapeutic effects mediated by at least two HDACi against different primary Eμ-myc lymphomas and a genetically distinct solid organ malignancy.
IFN-γ has a key role in mediating anti-cancer effects of vorinostat
Our previous study (26) Fig. S4B ). We hypothesised that IFN-γR -/-mice have inherently elevated IFN-γ levels. Indeed, naive and lymphoma-bearing IFN-γR -/-mice had significantly higher levels of serum IFN-γ than wild type mice ( Fig. 5A and B respectively). Furthermore, when lymphoma-bearing IFN-γR -/-mice were treated with an IFN-γ-inducing agent [α-GalCer-pulsed tumor cell vaccine (26)], IFN-γR -/-mice produced significantly higher levels of serum IFN-γ than equivalently treated, lymphoma-bearing WT mice (Fig. 5B) . The role of IFN-γ in delaying progression of Eμ-myc lymphoma was confirmed when IFN-γR -/-mice treated with a neutralizing anti-IFN-γ monoclonal antibody (mAb) succumbed to transplanted Eμ-myc lymphoma at a similar time to WT mice, which was significantly earlier than control Fig. 4B ). IFN-γ has been shown to both inhibit (28) and enhance (29) proliferation of tumor cells, and has been shown to induce tumor cell apoptosis (30) .
However, treatment of Eμ-myc cells with IFN-γ in vitro did not inhibit proliferation ( Supplementary Fig. S4C ) nor induce apoptosis ( Supplementary Fig. S4D ) regardless of addition of vorinostat. Similarly, expression of the dnIFN-γ did not alter proliferation of Eμ-myc cells ( Supplementary Fig. S4E ), nor influence sensitivity to vorinostat ( Supplementary Fig. S4F ). IFN-γ may also enhance tumor cell immunogenicity (31, 32) . Indeed, treatment of Eμ-myc cells with IFN-γ and vorinostat enhanced the expression of MHC class I and II above levels induced by each agent alone in a manner dependent on functional IFN-γR signaling ( Supplementary Fig. S5 ). The importance of tumor cell-restricted IFN-γR signaling for sustained in vivo responses to vorinostat was investigated. Treatment of mice bearing dnIFN-γR Eμ-myc lymphoma with vorinostat significantly enhanced survival compared to control treatment, however, vorinostat-treated mice bearing dnIFN-γR Eμ-myc lymphoma succumbed to lymphoma significantly earlier than vorinostattreated mice bearing EV Eμ-myc lymphoma (Fig. 5E ). These data demonstrate that 
Given the role of IFN-γ during vorinostat treatment and the enhanced immunogenicity of tumor cells by IFN-γ and vorinostat, we hypothesised CTLs may be a key effector cell of the anti-tumor immune response. Thus, WT mice bearing established Eμ-myc lymphoma were depleted specific lymphocyte subsets and treated with vorinostat.
However, despite efficient depletion from peripheral blood (Supplementary Fig. S6 
Our study provides direct experimental evidence demonstrating the functional importance of the host immune system in mediating sustained anti-tumor responses to HDACI. We have identified key immune cells (B cells) and effector molecules (IFN-γ) that play important roles in significantly augmented HDACi efficacy in pre-clinical models. Moreover, using α-GalCer we have identified a novel combination strategy to exploit the functional interplay between IFN-γ and HDACi that was well tolerated and therapeutically advantageous. Figure 7 on Ap cancerres.aacrjournals.org Downloaded from
